Treatment of C3 glomerulopathy with complement blockers

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 4, 2014, Pages 472-477

  Vivarelli, Marina ^a   Emma, Francesco ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

alternative pathway of complement; C3 glomerulopathy; C5b 9; dense deposit disease; eculizumab; membranoproliferative glomerulonephritis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; CR 1; ECULIZUMAB; SERINE PROTEINASE INHIBITOR; TRIPTERYGIUM WILFORDII EXTRACT; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3B RECEPTOR; CR1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLANT EXTRACT;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT C3 GLOMERULOPATHY; COMPLEMENT INHIBITION; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; GENE MUTATION; GENETIC POLYMORPHISM; GLOMERULOPATHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; TRIPTERYGIUM WILFORDII; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPLEMENT ALTERNATIVE PATHWAY; GENETICS; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; IMMUNOLOGY; METABOLISM; MUTATION; TRIPTERYGIUM;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; MUTATION; PLANT EXTRACTS; RECEPTORS, COMPLEMENT 3B; TRIPTERYGIUM;

EID: 84902254536     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1375299     Document Type: Article

References (30)

1. Pickering M. C., D'Agati V. D., Nester C. M., et al. C3 glomerulopathy: consensus report. Kidney Int: 2013; 84 6 1079 1089
2. Sethi S., Fervenza F. C. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost: 2014; 40 4 416 421
3. Xiao X., Pickering M. C., Smith R. JH. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin Thromb Hemost: 2014; 40 4 465 471
4. Sethi S., Nester C. M., Smith R. J. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int: 2012; 81 5 434 441
5. Sethi S., Fervenza F. C., Zhang Y., et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int: 2012; 82 4 465 473
6. Legendre C. M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med: 2013; 368 23 2169 2181
7. Zuber J., Fakhouri F., Roumenina L. T., Loirat C., Frémeaux-Bacchi V.; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol: 2012; 8 11 643 657
8. Nester C. M., Smith R. J. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens: 2013; 22 2 231 237
9. Zhang Y., Nester C. M., Holanda D. G., et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol: 2013; 24 11 1820 1829
10. Medjeral-Thomas N., Malik T. H., Patel M. P., et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int: 2014; 85 4 933 937
11. Gale D. P., de Jorge E. G., Cook H. T., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet: 2010; 376 9743 794 801
12. Malik T. H., Lavin P. J., Goicoechea de Jorge E., et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol: 2012; 23 7 1155 1160
13. Vernon K. A., Cook H. T. Complement in glomerular disease. Adv Chronic Kidney Dis: 2012; 19 2 84 92
14. Hawfield A., Iskandar S. S., Smith R. J. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy. Am J Kidney Dis: 2013; 61 5 828 831
15. Zipfel P. F., Lauer N. Defective complement action and control defines disease pathology for retinal and renal disorders and provides a basis for new therapeutic approaches. Adv Exp Med Biol: 2013; 735 173 187
16. Servais A., Noël L. H., Roumenina L. T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int: 2012; 82 4 454 464
17. Pickering M. C., Cook H. T., Warren J., et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet: 2002; 31 4 424 428
18. Pickering M. C., Warren J., Rose K. L., et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A: 2006; 103 25 9649 9654
19. Bomback A. S., Smith R. J., Barile G. R., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol: 2012; 7 5 748 756
20. Vivarelli M., Pasini A., Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med: 2012; 366 12 1163 1165
21. Daina E., Noris M., Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med: 2012; 366 12 1161 1163
22. Radhakrishnan S., Lunn A., Kirschfink M., et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med: 2012; 366 12 1165 1166
23. McCaughan J. A., O'Rourke D. M., Courtney A. E. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant: 2012; 12 4 1046 1051
24. Gurkan S., Fyfe B., Weiss L., Xiao X., Zhang Y., Smith R. J. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol: 2013; 28 10 1975 1981
25. Keating G. M. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs: 2013; 73 18 2053 2066
26. Nester C. M., Brophy P. D. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr: 2013; 25 2 225 231
27. Herlitz L. C., Bomback A. S., Markowitz G. S., et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol: 2012; 23 7 1229 1237
28. Hong Y., Zhou W., Li K., Sacks S. H. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney Int: 2002; 62 4 1291 1300
29. Wang J., Tang Z., Luo C., et al. Clinical and pathological features of dense deposit disease in Chinese patients. Clin Nephrol: 2012; 78 3 207 215
30. Appel G. B., Cook H. T., Hageman G., et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol: 2005; 16 5 1392 1403